Interventions for generalized anxiety disorder
- PMID: 36705012
- DOI: 10.1097/YCO.0000000000000840
Interventions for generalized anxiety disorder
Abstract
Purpose of review: To provide an overview of recently published work on anxiety, focusing on generalized anxiety disorder (GAD) and its treatment.
Recent findings: Self-reported anxiety symptoms were highly prevalent during the COVID-19 global pandemic in both the general population and in selected groups. There remains divided opinion about whether internet-based cognitive behavioural therapy (CBT) is noninferior to face-to-face CBT for GAD. A systematic review of drug treatment for GAD showed efficacy for selective serotonin reuptake inhibitors (SNRIs), agomelatine, and quetiapine. There may be a place for repetitive transcranial magnetic stimulation in the treatment of GAD. There was some evidence of efficacy for complementary therapies, including physical exercise, yoga, acupuncture, and Withania somnifera (ashwagandha). However, a systematic review of cannabidiol and tetrahydrocannabinol found insufficient evidence of efficacy in anxiety disorders.
Summary: Antidepressants and quetiapine show efficacy in the treatment of GAD. Internet-based psychological interventions have a place in the treatment of GAD when face-to-face treatment is inaccessible. There is increasing evidence for the use of physical exercise in the management of GAD. Some other complementary therapies, including cannabinoids, require further, methodologically sound, research.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Update on treatments for anxiety-related disorders.Curr Opin Psychiatry. 2023 Mar 1;36(2):140-145. doi: 10.1097/YCO.0000000000000841. Epub 2022 Dec 6. Curr Opin Psychiatry. 2023. PMID: 36480651 Review.
-
Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines.Health Technol Assess. 2017 Aug;21(45):1-138. doi: 10.3310/hta21450. Health Technol Assess. 2017. PMID: 28853392 Free PMC article. Clinical Trial.
-
Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials.Drug Des Devel Ther. 2016 Jan 12;10:259-76. doi: 10.2147/DDDT.S89485. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26834458 Free PMC article. Review.
-
Agomelatine in treating generalized anxiety disorder.Expert Opin Investig Drugs. 2014 Jun;23(6):857-64. doi: 10.1517/13543784.2014.911840. Epub 2014 Apr 28. Expert Opin Investig Drugs. 2014. PMID: 24766542 Review.
-
New approaches to the pharmacological management of generalized anxiety disorder.Expert Opin Pharmacother. 2013 Feb;14(2):175-84. doi: 10.1517/14656566.2013.759559. Epub 2013 Jan 3. Expert Opin Pharmacother. 2013. PMID: 23282069 Review.
References
-
- Yang X, Fang Y, Chen H, et al. Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019. Epidemiol Psychiatr Sci 2021; 30:e36.
-
- Thibodeau MA, Welch PG, Sareen J, Asmundson GJG. Anxiety disorders are independently associated with suicide ideation and attempts: propensity score matching in two epidemiological samples. Depress Anxiety 2013; 30:947–954.
-
- Delphino FM, da Silva CN, Jerônimo JS, et al. Prevalence of anxiety during the COVID-19 pandemic: a systematic review and meta-analysis of over 2 million people. J Affect Disord 2022; 318:272–282.
-
- Saeed H, Eslami A, Nassif NT, et al. Anxiety linked to COVID-19: a systematic review comparing anxiety rates in different populations. Int J Environ Res Public Health 2022; 19:2189.
-
- Johns G, Samuel V, Freemantle L, et al. The global prevalence of depression and anxiety among doctors during the COVID-19 pandemic: systematic review and meta-analysis. J Affect Disord 2022; 298 (Part A):431–441.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials